NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine

{
  "id": "MLC-T-ONC-015573",
  "term": "NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A peptide-based cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. Upon administration, NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. The NY-ESO-1, PRAME, MAGE-A3 and WT-1 peptides, tumor-associated antigens (TAAs) overexpressed in a variety of cancer cell types, play a key role in tumor cell proliferation.",
  "synonyms": [
    "NPMW peptide vaccine"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/ny-eso-1-prame-mage-a3-wt-1-peptide-vaccine/"
}